First Proteasome Inhibitor Approved for Multiple Myeloma

doi:10.1093/jnci/95.12.845

JNCI Journal of the National Cancer Institute 2003 95(12):845; doi:10.1093/jnci/95.12.845
© 2003 by Oxford University Press

This Article

	Full Text
	Alert me when this article is cited
	Alert me if a correction is posted

Services

	Email this article to a friend
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Personal Archive
	Download to citation manager
	Search for citing articles in: ISI Web of Science (17)
	Request Permissions

Google Scholar

	Articles by Twombly, R.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Twombly, R.

Social Bookmarking

	What's this?

Journal of the National Cancer Institute, Vol. 95, No. 12, 845, June 18, 2003
© 2003 Oxford University Press

NEWS

First Proteasome Inhibitor Approved for Multiple Myeloma

Renee Twombly

The first 10% of the full text of this article appears below.

Velcade (bortezomib), the first in a new class of investigationaldrugs known as proteasome inhibitors, was approved for use inmultiple myeloma in record-making time—only 4 months afterit had been submitted to the U.S. Food and Drug Administration.

"The drug shows a significant effect on patients with multiplemyeloma that have not responded to other treatments—aresponse that is likely to result in . . . [Full Text of this Article]

Add to CiteULike CiteULike Add to Connotea Connotea Add to Del.icio.us Del.icio.us What's this?

This article has been cited by other articles:

J. Voortman, E. F. Smit, R. Honeywell, B. C. Kuenen, G. J. Peters, H. van de Velde, and G. Giaccone
A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors
Clin. Cancer Res., June 15, 2007; 13(12): 3642 - 3651.
[Abstract] [Full Text] [PDF]

C.-H. Leung, S. P. Grill, W. Lam, W. Gao, H.-D. Sun, and Y.-C. Cheng
Eriocalyxin B Inhibits Nuclear Factor-{kappa}B Activation by Interfering with the Binding of Both p65 and p50 to the Response Element in a Noncompetitive Manner
Mol. Pharmacol., December 1, 2006; 70(6): 1946 - 1955.
[Abstract] [Full Text] [PDF]

C.-H. Leung, S. P. Grill, W. Lam, Q.-B. Han, H.-D. Sun, and Y.-C. Cheng
Novel Mechanism of Inhibition of Nuclear Factor-{kappa}B DNA-Binding Activity by Diterpenoids Isolated from Isodon rubescens
Mol. Pharmacol., August 1, 2005; 68(2): 286 - 297.
[Abstract] [Full Text] [PDF]

R. E. Brown, M. Lun, J. W. Prichard, T. M. Blasick, and P. L. Zhang
Morphoproteomic and Pharmacoproteomic Correlates in Hormone-Receptor-Negative Breast Carcinoma Cell Lines
Ann. Clin. Lab. Sci., July 1, 2004; 34(3): 251 - 262.
[Abstract] [Full Text] [PDF]

				C.-H. Leung, S. P. Grill, W. Lam, W. Gao, H.-D. Sun, and Y.-C. Cheng Eriocalyxin B Inhibits Nuclear Factor-{kappa}B Activation by Interfering with the Binding of Both p65 and p50 to the Response Element in a Noncompetitive Manner Mol. Pharmacol., December 1, 2006; 70(6): 1946 - 1955. [Abstract] [Full Text] [PDF]

				C.-H. Leung, S. P. Grill, W. Lam, Q.-B. Han, H.-D. Sun, and Y.-C. Cheng Novel Mechanism of Inhibition of Nuclear Factor-{kappa}B DNA-Binding Activity by Diterpenoids Isolated from Isodon rubescens Mol. Pharmacol., August 1, 2005; 68(2): 286 - 297. [Abstract] [Full Text] [PDF]

				R. E. Brown, M. Lun, J. W. Prichard, T. M. Blasick, and P. L. Zhang Morphoproteomic and Pharmacoproteomic Correlates in Hormone-Receptor-Negative Breast Carcinoma Cell Lines Ann. Clin. Lab. Sci., July 1, 2004; 34(3): 251 - 262. [Abstract] [Full Text] [PDF]